Eton Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Eton Pharmaceuticals es Sean Brynjelsen , nombrado en Jun 2017, tiene una permanencia de 7.42 años. compensación anual total es $1.75M, compuesta por 33.9% salario y 66.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.16% de las acciones de la empresa, por valor de $10.77M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 7.2 años, respectivamente.
Información clave
Sean Brynjelsen
Chief Executive Officer (CEO)
US$1.7m
Compensación total
| Porcentaje del salario del CEO | 33.9% |
| Permanencia del CEO | 7.4yrs |
| Participación del CEO | 4.2% |
| Permanencia media de la dirección | 2.6yrs |
| Promedio de permanencia en la Junta Directiva | 7.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Nov 14
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
Oct 07After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | US$913k |
| Dec 31 2023 | US$2m | US$592k | -US$936k |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$234k |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$2m | US$570k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$2m | US$542k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$476k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$2m | US$410k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$493k | US$332k | -US$37m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$654k | US$172k | -US$13m |
Compensación vs. Mercado: La compensación total ($USD1.75M) de Sean está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: La compensación de Sean ha sido consistente con los resultados de la empresa en el último año.
CEO
Sean Brynjelsen (52 yo)
7.4yrs
Permanencia
US$1,747,045
Compensación
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.4yrs | US$1.75m | 4.16% $ 10.8m | |
| CFO, Treasurer & Secretary | 2.6yrs | US$785.14k | 0.049% $ 126.3k | |
| Chief Business Officer | 1.7yrs | US$719.08k | 0.081% $ 208.4k | |
| Senior Vice President of Quality & Operations | less than a year | sin datos | sin datos | |
| Vice President of Sales Operations | no data | sin datos | sin datos | |
| Executive VP of Commercial Operations | 2.8yrs | sin datos | sin datos |
2.6yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ETON se considera experimentado (2.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.4yrs | US$1.75m | 4.16% $ 10.8m | |
| Independent Director | 7.2yrs | US$129.50k | 0.23% $ 598.7k | |
| Independent Director | 7.4yrs | US$126.90k | 0.26% $ 685.6k | |
| Independent Chairman | 7.2yrs | US$155.50k | 0.23% $ 598.7k | |
| Independent Director | 3.7yrs | US$119.10k | sin datos |
7.2yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de ETON se considera experimentada (7.2 años de antigüedad promedio).